IGF-1 et therapeutique du diabete non-insulino-dependant et de l'insulinoresistance

E. R. Froesch, T. Bianda, M. A. Hussain

Research output: Contribution to journalReview articlepeer-review

13 Scopus citations


Recombinant DNA technology has made large amounts of insulin-like growth factor-I (IGF-I) available for studies in animal models and humans. It has been shown that treatment with IGF-I is associated with increased insulin sensitivity in normal subjects as well as in patients with growth hormone deficiency, Type 1 and Type 2 diabetes mellitus and type A insulin- resistance. The metabolic effects of IGF-I appear to be beneficial in these conditions. The reported side effects of IGF-I, which may be largely due to overdosage, have limited its use to small and mostly short-term clinical studies.

Original languageEnglish (US)
Pages (from-to)261-267
Number of pages7
JournalDiabetes and Metabolism
Issue number4
StatePublished - Jul 1 1996
Externally publishedYes


  • Type 2 diabetes mellitus
  • growth hormone
  • insulin resistance
  • insulin sensitivity
  • insulin-like growth factor-I

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Endocrinology


Dive into the research topics of 'IGF-1 et therapeutique du diabete non-insulino-dependant et de l'insulinoresistance'. Together they form a unique fingerprint.

Cite this